FDA’s final guidance on a program for encouraging the use of continuous manufacturing and other new pharmaceutical technologies clarifies the types of emerging technologies that are eligible for review under the agency's Emerging Technology Program.
FDA Clarifies Scope Of Its Emerging Technology Program
FDA has issued final guidance that clarifies the types of technologies eligible for acceptance into the agency's Emerging Technology Program. FDA also issues internal guidance to explain how reviewers should handle emerging technology applications.
More from Manufacturing
More from Compliance
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Results from a single-arm study cannot support representations on overall survival, progression-free survival and disease control rate for the cancer drug, the Office of Prescription Drug Promotion said in another “untitled” letter implicating the agency’s CFL guidance.